BDNF Release and Signaling are Required for the Antidepressant Actions of GLYX-13

Conventional antidepressant medications, which act on monoaminergic systems, display significant limitations, including a time lag of weeks to months and low rates of therapeutic efficacy. GLYX-13 is a novel glutamatergic compound that acts as an NMDA modulator with glycine-like partial agonist prop...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Psychiatry
Main Authors: Kato, Taro, Fogaça, Manoela V., Deyama, Satoshi, Li, Xiao-Yuan, Fukumoto, Kenichi, Duman, Ronald S.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5988860/
https://ncbi.nlm.nih.gov/pubmed/29203848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mp.2017.220
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki